rs587777380 — DYRK1B H90P / H90R

Multi-allelic pathogenic locus — both H90P (T>G) and H90R (T>C) disrupt the DYRK1B DH box, causing AOMS3 (early-onset central obesity, type 2 diabetes, hypertension, coronary artery disease) via impaired kinase maturation

See your personal result for DYRK1B

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

DYRK1B H90P — The Metabolic Syndrome Gene

DYRK1B (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1B) is a serine/threonine kinase that plays a pivotal role in adipogenesis, glucose homeostasis, and hedgehog/Wnt signaling pathways. When functioning normally, DYRK1B helps restrain fat cell differentiation and maintain metabolic balance. The H90P variant disrupts a critical structural element of the kinase, triggering a cascade of metabolic consequences that manifest as AOMS311 AOMS3
Abdominal Obesity-Metabolic Syndrome 3, OMIM #615812, a rare autosomal dominant condition causing severe early-onset metabolic syndrome.

The Mechanism

The H90P mutation replaces histidine with proline at position 90 of the protein, within the DYRK homology (DH) box22 DYRK homology (DH) box
A conserved structural element immediately preceding the catalytic domain, critical for proper kinase folding through tyrosine autophosphorylation. This box normally stabilizes interactions with the catalytic domain during protein maturation. The substitution impairs tyrosine autophosphorylation (reduced ~80% versus wild-type), causing mutant DYRK1B to misfold and accumulate in detergent-insoluble cytoplasmic aggregates. The result is a net loss of functional DYRK1B activity.

Without adequate DYRK1B function, two main pathological effects follow: enhanced adipogenesis — preadipocytes differentiate more readily into fat cells, leading to accelerated visceral fat accumulation — and impaired glucose regulation — hepatic glucose-6-phosphatase expression rises, driving excess hepatic glucose output and contributing to frank type 2 diabetes. Downstream, the RAS–RAF–MEK pathway is dysregulated, and suppression of hedgehog and Wnt signaling further promotes adipogenic commitment of precursor cells.

The Evidence

The H90P variant was first described in 201433 first described in 2014
Keramati AR et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med. 2014;370(20):1909-19 through genetic linkage analysis and whole-exome sequencing of three large Iranian families with autosomal dominant metabolic syndrome. H90P co-segregated with disease in an ethnically distinct family alongside the R102C mutation, producing an identical phenotype: early-onset central obesity, type 2 diabetes, hypertension, and coronary artery disease (myocardial infarction between ages 50–60). No unaffected carrier was identified in any family, suggesting high penetrance.

Molecular characterization44 Molecular characterization
Abu Jhaisha S et al. DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain. Sci Rep. 2017;7(1):7602 confirmed that H90P — unlike the structurally intact mature kinase — fails to properly autophosphorylate on tyrosine. The mutant protein relies abnormally on the HSP90–CDC37 chaperone complex for stability, rendering it sensitive to HSP90 inhibition. This chaperone dependency is a therapeutic vulnerability that has been proposed as a drug target.

A 2024 Diabetes Care study55 2024 Diabetes Care study
Folon L et al. Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes. Diabetes Care. 2024 across 9,353 participants quantified the effect: pathogenic DYRK1B loss-of-function variants were associated with an 8.0-unit higher BMI (OR 7.9 for obesity) and OR 4.8 for type 2 diabetes. The same study confirmed that H90P-class variants cause monogenic obesity, a clinically distinct entity from polygenic common obesity.

What This Means Clinically

AOMS3 is frequently misdiagnosed. A 2024 case report66 2024 case report
Abdominal Obesity-Metabolic Syndrome 3 Misclassified as Type 1 Diabetes Mellitus. 2024 documented a patient treated with 225 units of insulin daily for 15 years before the DYRK1B mutation was identified. Switching to oral agents (metformin, pioglitazone, dapagliflozin) plus semaglutide reduced HbA1c from 13% to 7% within 6 months — a result insulin alone had never achieved. DYRK1B carriers respond better to insulin-sensitizing agents and GLP-1 receptor agonists than to exogenous insulin.

Because this is an autosomal dominant condition, each first-degree relative of a carrier has a 50% chance of inheriting the variant. Early identification before metabolic complications emerge allows preventive intervention.

H90R — The Second Allele at This Codon

This locus is multi-allelic: in addition to H90P (T>G), a T>C change at the same position produces H90R (His90Arg). H90R has not been individually characterised in cell-based assays, but its structural logic is equivalent — arginine, like proline, disrupts the local backbone geometry of the DH box required for tyrosine autophosphorylation during kinase maturation. Population data (gnomAD v4 exomes, ~3 alleles in 800,000) confirms the same extreme rarity as H90P. H90R is classified as likely pathogenic by structural inference; clinical management for carriers is identical to H90P.

Interactions

H90P and H90R act at the same codon as the R102C variant (encoded by a distinct mutation in the same DYRK1B gene at codon 102). All three disrupt the DH box and produce clinically indistinguishable AOMS3. Functional studies on H90P and R102C show overlapping mechanisms — impaired DH-box-mediated kinase maturation, enhanced chaperone dependency, and downstream adipogenic dysregulation — making them phenotypic equivalents despite different amino acid substitutions.

Genotype Interpretations

What each possible genotype means for this variant.

TT Non-Carrier Normal

No DYRK1B H90P mutation — standard AOMS3 risk

You do not carry the DYRK1B H90P mutation. This pathogenic variant is exceptionally rare globally (gnomAD allele frequency ~0.000004 in Europeans, essentially absent in other populations). Your DYRK1B kinase activity is not affected by this specific mutation, and you are not at elevated risk for AOMS3 from this variant.

GT AOMS3 Carrier High Risk

One copy of the DYRK1B H90P mutation — high risk for early-onset metabolic syndrome

DYRK1B H90P disrupts the DH (DYRK homology) box, a structural element critical for the kinase to fold and activate properly through tyrosine autophosphorylation. The mutant protein misfolds, accumulates as aggregates, and is sequestered by the HSP90-CDC37 chaperone complex. The net effect is loss of DYRK1B function, leading to enhanced adipogenesis (visceral fat accumulation) and upregulated hepatic glucose-6-phosphatase expression (driving excess hepatic glucose output).

Unlike common polygenic obesity and type 2 diabetes, this is a Mendelian disease. The diabetes is caused by a combination of insulin resistance and impaired beta-cell insulin secretion — a mechanism that responds better to insulin sensitizers (metformin, pioglitazone, GLP-1 receptor agonists) than to exogenous insulin. Correctly reclassifying AOMS3 enables a dramatic treatment shift. A documented case achieved HbA1c from 13% to 7% within 6 months of switching from high-dose insulin to oral agents plus semaglutide.

GG Homozygous H90P High Risk

Two copies of the DYRK1B H90P mutation — severe early-onset metabolic syndrome

You carry two copies of the DYRK1B H90P mutation. This genotype is extraordinarily rare — no homozygous cases have been formally reported in the published AOMS3 literature, which has focused on heterozygous carriers. Given the autosomal dominant nature of AOMS3, a homozygous state would be expected to produce at least as severe a phenotype as heterozygosity, and potentially more severe, though the clinical picture cannot be precisely predicted from published case data.

The same management principles as for heterozygous carriers apply, with heightened urgency for specialist evaluation and cardiovascular monitoring.

CT H90R Carrier High Risk

One copy of the DYRK1B H90R variant — likely elevated risk for early-onset metabolic syndrome

You carry one copy of the DYRK1B H90R variant, a rare missense mutation at the same codon (histidine 90) as the established pathogenic H90P allele. This position lies within the DYRK homology (DH) box, the structural element essential for DYRK1B kinase maturation. H90R has not been individually studied in cell lines, but its structural location — identical to the H90P pathogenic hotspot — and its extreme population rarity (~3 observed alleles out of 800,000 in gnomAD) are consistent with high-penetrance pathogenic behaviour.

Clinical features associated with DYRK1B DH-box disruption include central obesity beginning in childhood or early adulthood, labile type 2 diabetes that responds poorly to standard insulin regimens, hypertension emerging in the fifth decade, and early-onset coronary artery disease. As an autosomal dominant condition, a single copy is sufficient for disease.

CC Homozygous H90R High Risk

Two copies of the DYRK1B H90R variant — severe metabolic syndrome risk requiring immediate specialist evaluation

You carry two copies of the H90R allele at DYRK1B codon 90. This genotype is extraordinarily rare — no homozygous cases have been reported. Given the autosomal dominant nature of AOMS3, homozygosity would be expected to produce at least as severe a clinical phenotype as heterozygosity. Urgent specialist evaluation is indicated.